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Abstract
BACKGROUND: There is a reason to believe that the polymorphism of genes encoding some enzymes and 
receptors plays a role in increasing of restenosis development risk. It is common knowledge that ethnicity affects 
the frequency of heterozygous genotypes occurrence. There is the evidence that polymorphism of the FGB gene 
(rs1800790) and THBD gene was determined in the ethnic group of Kazakhs with restenosis of the coronary arteries, 
which can be considered as genetic predictors of restenosis development. Today, the questions of the role of the 
genetic component in the development of coronary heart disease (CHD) remain open.
AIM: Evaluation of gene polymorphism in patients with restenosis of coronary arteries after stent installation.
MATERIALS AND METHODS: The group consisted of Kazakh population of the age category from 45 to 65 years 
of both sexes: Group I (50 persons) patients with a diagnosis of CHD, with a fixed stent and the development 
of restenosis during the year; Group 2 (58 persons) – with a fixed stent and no restenosis during the year. The 
association of genetic polymorphisms was evaluated in accordance with the case–control design based on the 
generalized linear model assuming a log-additive inheritance model.
RESULTS: Thus, when comparing two groups using five patterns of inheritance, the following SNP were revealed: 
Codominant inheritance pattern – rs1045642 (p = 0.0427), dominant inheritance pattern – rs12041331 (p = 0.036088), 
rs13431554 (p = 0.025461), and rs1045642 (p = 0.012774), and overdominant inheritance pattern – rs12041331 
(p = 0.051736), rs5918 (p = 0.057652), and rs13431554 (р = 0.036006). Thus, three SNPs associated with stenting were 
identified: rs7543130 (p = 0.009324), rs6785930 (p = 0.016858), and rs7819412 (p = 0.061325) and two SNPs associated 
with the development of restenosis after stent placement: rs1061781 (p = 0.063184) and rs342293 (p = 0.061636).
CONCLUSION: The polymorphisms associated with the risk of developing restenosis after stenting were determined: 
Codominant inheritance pattern – one polymorphism (rs1045642, p = 0.0427); dominant inheritance pattern 
– three polymorphisms (rs12041331, p = 0.036088; rs13431554, p = 0.025461; rs1045642, p = 0.012774), and 
overdominant inheritance pattern – one polymorphism (rs13431554, p = 0.036006). Based on the hybrid machine 
learning approach (RuleFit), four rules were obtained for assessing the empirical risk of restenosis developing after 
stenting – from 20% to 40%.
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Introduction
The significance of personalized medicine 
development determines the necessity of individual 
approach to the treatment and prevention of heart 
diseases and requires accounting molecular and 
biological differences, and above all the genetic 
conditionality of pathology.
There is evidence of the influence of various 
factors on the risk of coronary artery restenosis 
development: From the intracoronary intervention, 
the age of the patient, the concomitant diseases, the 
degree and extent of the lesion, the length of the lesion, 
the diameter of the vessel lumen after implantation, and 
etc., to the resistance to pharmacotherapy.
Personalized medicine is a promising direction 
in the medical science development, aimed at the 
assessing of the specific biomarkers of the disease, as 
well as the genetic profile of the patient, which is a key 
point in the increasing of the treatment effectiveness.
Endovascular treatment methods, such 
as stenting of coronary arteries, are widespread 
in the treatment of coronary heart disease (CHD), 
but restenosis in the stent is the main limitation of 
this method effectiveness, and even the use of 
drug-coated stents has not completely resolved the 
problem [1].
Stenting of the coronary arteries remains an 
effective method at coronary arteries revascularization, 
in this regard, the search for new predictors of restenosis 
development after stent fixing is relevant.
There is a reason to believe that the 
polymorphism of genes encoding some enzymes 
and receptors plays a role in increasing of restenosis 
development risk [2]. A number of large-scale programs 
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(aimed at studying of restenosis genetics) are currently 
known, such as genetic determinants of restenosis, 
Coronary AngioPlasty Amlodipine REStenosis Study, 
research, and ISAR-strut thickness effect on restenosis 
outcome 2 [3], [4]. The development of restenosis in the 
stent can also indirectly depend on polymorphisms in 
the genes of the hemostatic system, renin-angiotensin 
system, and antioxidant system [5].
As it is known that L54M (rs854560) and 
Q192R (rs662) polymorphisms have the greatest 
clinical significance among all the polymorphic variants 
of the PON1 gene [6], [7], [8], [9]. The CYP2C19 
gene has nine exons and it is highly polymorphic with 
more than 25 allele variants [5]. Using an algorithm 
in the R statistics environment of the SNPedia base, 
it was performed an analysis for the presence of 
PON1, CYP2C19 gene variations as predictors of the 
risk of development of coronary artery disease and 
coronary artery restenosis. The distribution data were 
obtained in various populations of the following alleles 
– L54M (rs854560) and Q192R (rs662) rs12248560, 
rs41291556, rs41291556, rs72552267, rs4986893, 
rs4244285, rs72558186 (A) represents SNP CYP2C19, 
and rs56337013.
It is common knowledge that ethnicity affects 
the frequency of heterozygous genotypes occurrence. 
Thus, there is the evidence that the frequency of the 
occurrence of heterozygous genotypes of CYP1C19*2GA 
(*1/*2) alleles ranges from 28% to 60% in the Asian 
population, according to various authors [5], [9]. As a 
result of scientific research, there was a difference 
in the prevalence of polymorphism of the CYP2C19 
isoenzyme in different ethnic groups. The frequency of 
the occurrence of this allele is about 12% in Europeans, 
12% in African-Americans, and 29–35% in Asians [5]. 
According to other sources [9], the prevalence of the 
allele with the CYP2C19*2 genotype is about 25–30% 
in Europeans and 50–60% in Asians [5].
A decrease in the effectiveness of clopidogrel 
antiplatelet agent in different patients depending 
on ethnic groups is associated with the genetic 
polymorphism of CYP2C19, which also increases the 
risk of coronary artery restenosis.
There is the evidence that polymorphism of the 
FGB gene (rs1800790) and THBD gene was determined 
in the ethnic group of Kazakhs with restenosis of the 
coronary arteries, which can be considered as genetic 
predictors of restenosis development [10].
It was demonstrated that the distribution 
frequency of the *2 allele (GA and AA) for the G681A 
polymorphic marker CYP2C19 gene in patients of 
Kazakh nationality with acute coronary syndrome 
was 27% and 2%, respectively, while the distribution 
frequency for the allele *3 (GA and AA) amounted to 9% 
and 1%, respectively [11].
Today, the questions of the role of the genetic 
component in the development of CHD remain 
open, in particular, at the risk of repeated stenosis 
developing in the area of the stent installation, as well 
as in determining its significance in the structure of 
risk factors and causes in cases of low effectiveness 
of therapy, which is generally aimed at optimizing of a 
personalized approach in the treatment and tactics of 
monitoring the patients with coronary artery disease.
Methods
The studies were conducted on the base of 
Karaganda Medical University, clinics of Karaganda. 
Permission of the Committee on Bioethics of KSMU 
No.305 dated May 19, 2017, was obtained for research 
conduction.
The persons of Kazakh ethic nationality were 
included to the study. Group I consisted of 50 persons 
of the age category from 45 to 65 years of both sexes. 
Inclusion criteria: Patients with a diagnosis of CHD, with 
a fixed stent and the development of restenosis during 
the year (according to coronary angiography and medical 
records) based on the recommendation of the European 
Society of Cardiology (ESC). Group 2 consisted of 58 
persons at the age from 45 to 65 years of both sexes. 
Inclusion criteria: Patients with a diagnosis of coronary 
artery disease, with a fixed stent and no restenosis 
during the year (according to the medical record) based 
on the recommendation of the ESC.
Exclusion criteria for Groups 1 and 2: Chronic 
heart failure in the stage of decompensation (Stage II B 
according to the classification of Strazhesko–Vasilenko 
and FC IV according to NYHA); life-threatening heart 
rhythm disturbances; chronic rheumatic heart disease; 
acute cerebrovascular accident; bronchial asthma; 
chronic obstructive pulmonary disease of 2–3 stage; 
decompensated liver cirrhosis; severe renal impairment 
(glomerular filtration rate <30 ml/min); malignant 
neoplasms; morbid obesity; and the presence of gout.
The association of genetic polymorphisms was 
evaluated in accordance with the case–control design 
based on the generalized linear model assuming a log-
additive inheritance model.
Statistical analysis was carried out in the 
programs of R statistics (Compare Groups R packages 
http://www.jstatsoft.org/ [10]), Statistica 6.0 (Stat-Soft), 
and SPSS (IBM) under the following conditions:
•	 Quantitative data with normal distribution: 
Student’s t-test for two groups or analysis of 
variance, when the number of groups is more 
than 2;
•	 Quantitative data with abnormal distribution: 
Non-parametric Mann–Whitney and Kruskal–
Wallis criteria for independent groups and 
Wilcoxon’s criterion for dependent groups;
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•	 Categorical data: Chi-square criterion or 
Fisher’s exact test if necessary (when the 
expected frequency is <5 in one of the cells).
Assessment of the data distribution (normality 
test) was carried out on the basis of the Shapiro–Wilks 
criterion. p < 0.05 was taken for the level of statistical 
significance of differences in indicators. The data in 
the text and tables are presented as the median (Me), 
quartile 1, and quartile 3 (Q1, Q3).
The study of the markers diagnostic value 
was carried out using receiver operating characteristic 
curves, which reflect the specificity and sensitivity of 
the test. The quality of the model with the area under 
the curve (AUC): 0.9–1.0 is considered to be excellent, 
0.9–0.8 – very good, and 0.7–0.8 – good.
Search and assessment of risk factors 
associated with the phenotype (disease) were carried 
out using RuleFit – a hybrid algorithm for regression 
and classification with increasing gradient and LASSO – 
algorithm for training a highly accurate and interpretable 
model (Figure 1) [11].
Results
To identify statistically significant genetic 
polymorphisms with the development of restenosis, two 
groups were selected: Patients with stenting without 
restenosis (this group was considered as a control) 
and patients with the development of restenosis in the 
course of the past year.
As the number of patients in each group is 
relatively small, five different inheritance models were 
used to identify the genotype-phenotype association: 
Dominant, codominant, recessive, overdominant, and 
log-additive models of inheritance. The results of the 
analysis are presented in Figure 2 and Table 1.
Table 1: Table of genetic polymorphisms associated with 
restenosis after stent fixation
Polymorphism Inheritance models р Comment
rs1045642 Codominant 0.0427 -
rs12041331 Dominant 0.036088 -
rs13431554 Dominant 0.025461 -
rs1045642 Dominant 0.012774 -
rs12041331 Overdominant 0.051736 Close to threshold value
rs5918 Overdominant 0.057652 Close to threshold value
rs13431554 Overdominant 0.036006 -
The analysis revealed a total of four 
different polymorphisms that are associated with the 
development of restenosis. Assuming a codominant 
inheritance model, one polymorphism was identified, 
assuming a dominant and overdominant inheritance 
model – three SNPs each. In the recessive and log-
additive model of inheritance, statistically significant 
polymorphisms associated with the development of 
restenosis were not obtained.
Two machine learning methods were used 
to assess the associations of polymorphisms and the 
development of restenosis: Additive Tree [11], [12] and 
RuleFit [13].
All missing values (positions in which genotypes 
were not determined for certain reasons) were filled 
using the Random Forest algorithm (RF = Random 
forest).
As a result of training based on genotypes 
associated with the risk of developing restenosis, it was 
obtained a model with indicators of 100% specificity and 
89% sensitivity (Figure 3). The resulting trained model 
based on the additive tree algorithm had 94% balanced 
accuracy of the predicted results.
Figure 1: Schematic representation of the analysis stages based on the RuleFit hybrid algorithm
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Figure 3: Indicators of a trained model based on additive tree 
(genotype-restenosis)
Based on the trained model, a decision 
tree was obtained – an algorithm for analyzing the 
genotype-restenosis association (Figure 4). As shown 
in this diagram, the total number of polymorphisms that 
predict the development of restenosis is nine SNPs. The 
starting position is the determination of the genotypes 
of rs1045642 polymorphism.
The machine learning model (RuleFit) after 
learning achieved the following indicators: Sensitivity 
91%, specificity 75%, and AUC 90% (Figure 5). This 
model had a balanced forecast accuracy of 83%.
This model identified four rules (genotypes 
of certain polymorphisms) among 519 rules for 
the assessment of the empirical risk of restenosis 
developing (Table 2).
Table 2: Table of rules for associations of polymorphism 
genotypes with the empirical risk of restenosis
Rule Cases Empirical risk of restenosis
rs1045642<=2.5 + rs12041331>2.5 + 
rs1501908<=1.5
20 0.4
rs1045642<=2.5 + rs13431554<=1.5 + 
rs6102059>1.5 + rs174547>1.5
14 0.286
rs1045642<=2.5 + rs12041331>2.5 + rs662<=2.5 
+ rs4977574>1.5
13 0.231
rs762551<=1.5 + rs13431554<=1.5 + 
rs291096>1.5 + rs12248560<=1.5
10 0.2
It should be noted that these machine learning 
methods work with quantitative data and it required the 
encoding of genotypes into integer values.
Figure 2: Graphic diagram of p-values obtained when calculating the genotype-restenosis association after stent fixation
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Figure 4: The decision tree algorithm for evaluating the genotype-restenosis association (orange – restenosis after stenting, turquoise – 
stenting without restenosis (control), gray –intermediate state that requires the following definition of polymorphism)
Figure 5: Indicators of a trained model based on RuleFit (empirical risk of restenosis developing after stenting)
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Thus, when comparing two groups (patients 
without stent restenosis and patients with stent and 
restenosis) using five patterns of inheritance, the 
following SNP was revealed: Codominant inheritance 
pattern – rs1045642 (p = 0.0427), dominant inheritance 
pattern – rs12041331 (p = 0.036088), rs13431554 
(p = 0.025461), and rs1045642 (p = 0.012774), and 
overdominant inheritance pattern – rs12041331 
(p = 0.051736), rs5918 (p = 0.057652), and rs13431554 
(р = 0.036006).
The model, trained on the results of genotyping 
in patients with the development of restenosis 
after stent fixing using the additive tree algorithm, 
possessing high specificity (100%), sensitivity (89%), 
and 94% balanced prediction accuracy, allowed us to 
create a diagnostic association assessment algorithm 
polymorphisms with a risk of developing restenosis 
after stenting in the decision tree form. The decision 
tree is based on the determination of the rs1045642 
genotype with a pharmacogenetic profile, including 
the risk of restenosis developing in the treatment by 
clopidogrel.
Machine learning based on the RuleFit 
algorithm with 91% sensitivity, 75% specificity, and 
83% prognostic accuracy allowed to define a list of 
four rules for assessing the relationship of the totality of 
genotypes of certain polymorphisms with the empirical 
risk of restenosis developing after stenting.
The following gene combinations were 
identified during the detection of polymorphisms 
associated with restenosis against the background of 
antiplatelet therapy with clopidogrel: rs1045642<=2.5 
+ rs12041331>2.5 + rs1501908<=1.5 (revealed 
in 20 of 50 cases (40%). The combination of 
genes rs1045642<=2.5 + rs13431554<=1.5 + 
rs6102059>1.5 + rs174547>1.5 – was identified in 
28%. The combination of genes rs1045642<=2.5 
+ rs12041331>2.5 + rs662<=2.5 + rs4977574>1.5 
was revealed in 26% and the following combination 
rs762551<=1.5 + rs13431554<=1.5 + rs291096>1.5 + 
rs12248560<=1.5 in 20%.
The following assumptions were applied 
when analyzing the results of patients with a fixed 
stent without restenosis and a fixed stent with 
restenosis (p had a higher value, but close to 5%). 
Thus, three SNPs associated with stenting were 
identified: rs7543130 (p = 0.009324), rs6785930 
(p = 0.016858), and rs7819412 (p = 0.061325) and two 
SNPs associated with the development of restenosis 
after stent placement: rs1061781 (p = 0.063184) and 
rs342293 (p = 0.061636).
It should be noted that the Bonferroni correction 
for multiple comparisons did not reveal significant 
polymorphisms associated with the development of 
restenosis after stent fixing, which requires further 
research to increase the sample.
Discussion
As a result of the analysis of genotyping 
data, the polymorphisms associated with the risk of 
developing restenosis after stenting were determined: 
Codominant inheritance pattern – one polymorphism 
(rs1045642, p = 0.0427); dominant inheritance pattern 
– three polymorphisms (rs12041331, p = 0.036088; 
rs13431554, p = 0.025461; rs1045642, p = 0.012774), 
and overdominant inheritance pattern – one 
polymorphism (rs13431554, p = 0.036006).
Using machine learning, a diagnostic 
algorithm was obtained for assessing the association 
of polymorphisms with the risk of developing restenosis 
after stenting in the form of a decision tree based on 
the determination of the genotypes of rs1045642 
polymorphism.
Based on the hybrid machine learning approach 
(RuleFit), four rules were obtained for assessing the 
empirical risk of restenosis developing after stenting – 
from 20% to 40%.
The conducted studies allow considering 
the established polymorphisms as predictors of the 
repeated stenosis development of the coronary arteries 
in the stent installation area, which determines the 
importance of early genetic examination of patients 
with chronic coronary syndrome to develop the 
comprehensive treatment tactics and patient monitoring. 
The proposed decision tree with rs1045642 genotypes 
allows evaluating the pre-test probability of restenosis 
developing in patients with chronic coronary syndrome.
Conclusion
Thus, using machine learning, a diagnostic 
algorithm was obtained for assessing the association 
of polymorphisms with the risk of developing restenosis 
after stenting in the form of a decision tree, which is 
based on the determination of rs1045642 polymorphism 
genotypes. Based on the hybrid approach of machine 
learning (RuleFit), 4 rules for assessing the empirical 
risk of developing restenosis after stenting from 20 to 
40% were obtained.
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